High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Garufi, Alessia ^a,b   D'Orazi, Gabriella ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Apoptosis; Calyculin A; Chemotherapy; Gene transcription; Hyperglicemia; P53; Phosphatase; Ser46 phosphorylation

Indexed keywords

CALYCULIN A; CISPLATIN; DOXORUBICIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SERINE; SERINE 15; SERINE 46; UNCLASSIFIED DRUG; GLUCOSE; OXAZOLE DERIVATIVE; PHOSPHOPROTEIN PHOSPHATASE; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BIOCHEMICAL ANALYSIS; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MUTANT; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; TRANSCRIPTION INITIATION; UPREGULATION; WILD TYPE; ANTAGONISTS AND INHIBITORS; CELL NUCLEUS; DRUG EFFECTS; DRUG INTERACTION; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; METABOLISM; NEOPLASMS; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; DOXORUBICIN; DRUG INTERACTIONS; GLUCOSE; HCT116 CELLS; HUMANS; NEOPLASMS; OXAZOLES; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; SERINE; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929940889     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0079-4     Document Type: Article

References (54)

1. Kruse JP, Gu W: Modes of p53 regulation. Cell 2009, 137:609-622.
2. Vousden K.H. , Prives C: Blinded by the light: The growing complexity of p53. Cell2009, 137:413-431
3. Bode AM, Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004, 4:793-805.
4. Attardi L, DePinho A: Conquering the complexity of p53. Nat Genet 2004, 36:7-8.
5. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
6. Brooks CL, Gu W: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003, 15:164-171.
7. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y: p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102:849-862.
8. Mayo LD, Rok Seo Y, Jackson MW, Smith ML, Rivera Guzman JR, Koegaonkar CK, Donner DB: Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 2005, 280:25953-25959.
9. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S: Homeodomain-interacting protein kinase 2 phosphorylates p53 at Ser46 and mediates apoptosis. Nat Cell Biol 2002, 4:11-19.
10. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G: Homeodomaininteracting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 2004, 293:311-320.
11. Pistritto G, Puca R, Nardinocchi L, Sacchi A, D'Orazi G: HIPK2-induced p53Ser46 phosphorylation activates the KILLER/ DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ 2007, 14:1837-1839.
12. Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, Stunnenberg HG, Lohrum M: Role of p53 serine 46 in p53 target gene regulation. PLoS One 2011, 6:e17574.
13. Cecchinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, Gasbarri A, Ulivieri A, Del Prete F, Trovato M, Piaggio G, Bartolazzi A, Soddu S, Sciacchitano S: Repression of the anti-apoptotic molecule Galectin-3 by HIPK2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 2006, 26:4746-4757.
14. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC, Vassilev LT: Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004, 102:53015-53022.
15. Ichwan SJ, Yamada S, Sumrejkanchanakij P, Ibrahim-Auerkari E, Eto K, Ikeda MA: Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 2006, 25:1216-1224.
16. Nakamura Y, Futamura M, Kamino H, Yoshida K, Nakamura Y, Arakawa H: Identification of p53-46 F as super p53 with an enhanced ability to induce p53-dependent apoptosis. Cancer Sci 2006, 97:633-641.
17. Feng L, Hollstein M, Xu Y: Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 2006, 5:2812-2819.
18. Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, Wu E, Ma Q: Hyperglycemia, a neglected factor during cancer progression. BioMed Res Inter 2014, 2014:461917.
19. Cebioglu M, Schild HH, Golubnitschaja O: Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J 2010, 1:130-137.
20. Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS: Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst 2012, 104:1702-1711.
21. Zeng L, Biernacka KM, Holly JMP, Jarret C, Morrison AA, Morgan A, Winters ZE, Foulstone EJ, Shield JP, Perks CM: Hyperglicaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer 2010, 17:539-551.
22. Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, Perks CM, Holly JMP: Hyperglicaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocrinol J 2013, 20:741-751.
23. Ma YS, Yang IP, Tsai HL, Huang CW, Juo SHH, Wang JY: High glucose modulates antiproliferative effect and cytotoxicity of 5-Fluorouracil in human colon cancer cells. DNA and Cell Biol 2014, 33:64-72.
24. Shao Y, Ling CC, Liu XQ: High concentrations of glucose suppress etoposide-induced cell death of B-cell lymphoma through BCL-6. Biochem Biophys Res Commun 2014, 450:227-233.
25. Zhao Y, Coloff JL, Ferguson EC, Jacobs SR, Cui K, Rathmell JC: Glucose metabolism attenuates p53 and PUMA-dependent cell death upon growth factor deprivation. J Biol Chem 2008, 283:36344-36353.
26. Mi J, Bolesta E, Brautigan DL, Larner JM: PP2A regulates ionizing radiationinduced apoptosis through Ser46 phosphorylation of p53. Mol Cancer Ther 2009, 8:135-140.
27. Garufi A, D'Orazi V, Arbiser JL, D'Orazi G: Gentian violet induces p53 transactivation in cancer cells. Int J Oncol 2014, 44:1084-1090.
28. Nardinocchi L, Puca R, D'Orazi G: HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging-US 2011, 3:33-43.
29. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G: Targeting hypoxia in cancer cells by restoring homeodomain-interacting protein kinase 2 and p53 activity and suppressing HIF-1a. PLoS One 2009, 4:e6819.
30. Di Stefano V, Mattiussi M, Sacchi A, D'Orazi G: HIPK2 inhibits MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett 2005, 579:5473-5480.
31. Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D, D'Orazi G: Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Rad Biol Med 2010, 48:1338-1346.
32. Soussi T, Beroud C: Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer 2001, 1:233-240.
33. Hoe KK, Verma CS, Lane DP: Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014, 13:217-236.
34. Selivanova G, Wiman KG: Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007, 26:2243-2254.
35. Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D'Orazi V, Avantaggiati M, Crispini A, Pucci D, D'Orazi G: A fluorescent curcuminbased Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res 2013, 32:72.
36. D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A, Soddu S: Exogenous wt-p53 protein is active in transformed cells but not in their nontransformed counterparts: implications for cancer gene therapy without tumor targeting. J Gene Med 2000, 2:11-21.
37. Martins CP, Martins CP, Brown-Swigart L, Evan GI: Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1223-1234.
38. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T: Restoration of p53 function leads to tumor regression in vivo. Nature 2007, 445:661-665.
39. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
40. Mandinova A, Lee SW: The p53 pathway as a target in cancer therapeutics: obstacles and promise. Science 2011, 3:1-7.
41. Dai C, Gu W: p53 post-transaltional modification: deregulated in tumorigenesis. Trends Mol Med 2010, 16:528-536.
42. Li X, Dumont P, Della Pietra A, Shetler C, Mutphy ME: The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 2005, 280:24245-24251.
43. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagawara A, Kizaki H: Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 2008, 283:3979-3987.
44. Garufi A, Ricci A, Trisciuoglio D, Iorio E, Carpinelli G, Pistritto G, Cirone M, D'Orazi G: Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and therapeutical implications for tumor therapy. Cell Death Dis 2013, 4:e639.
45. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML: Dietary downregulation of mutant p53 levels via glucose restriction. Cell Cycle 2012, 11:4436-4446.
46. Pallavi R, Giorgio M, Pelicci PG: Insights into the beneficial effect of caloric/dietary restriction for a healthy and prolonged life. Front Physiol 2012, 3:318.
47. Castermans D, Somers I, Kriel J, Louwet W, Wera S, Versele M, Janssens V, Thevelein JM: Glucose-induced posttranslational activation of protein phosphatases PP2A and PP1 in yeast. Cell Res 2012, 22:1058-1077.
48. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW: ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 2002, 277:12491-12494.
49. Komiyama S, Taniguchi S, Matsumoto Y, Tsunoda E, Ohto T, Suzuki Y, Yin HL, Tomita M, Enomoto A, Morita A, Suzuki T, Ohtomo K, Hosoi Y, Suzuki N: Potentiality of DNA-dependent protein kinase to phosphorylate Ser46 of human p53. Biochem Biophys Res Commun 2004, 323:816-822.
50. Yoshida K, Liu H, Miki Y: Protein kinase C ä regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 2006, 281:5734-5740.
51. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K: DYRK2 is targeted to the nucleus to control p53 via ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 2007, 25:725-738.
52. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D'Orazi G: HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer 2009, 8:85.
53. D'Orazi G, Rinaldo C, Soddu S: Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res 2012, 31:63.
54. de la Vega L, Grishina I, Moreno R, Krüger M, Braun T, Schmitz ML: A redoxregulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Mol Cell 2012, 46:1-12.